Pharmaceutical Firms

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

IPA and Ind-Ra say Trump's MFN-based drug pricing move will impact innovators more than Indian generics, with CDMO firms likely to gain from offshore cost advantages

India's pharma market grows 7.8% in April, led by chronic therapies

Chronic therapies and price increases drove 7.8 per cent growth in India's pharma market in April 2025, with cardiac and gastrointestinal segments showing double-digit value gains

TPG acquires 35% in SCHOTT Poonawalla, SII retains minority stake

SCHOTT Pharma keeps 50% stake in Indian JV as TPG joins with Novo Holdings to support global pharma supply chain growth; deal expected to close in H1 2025

Ashish Kacholia portfolio stock surges 10% on strong Q4 performance

Share of Ami Organics surged 10% to ₹ 1,243 on the BSE in Friday's intra-day deal, after the company posted 144% YoY jump in its consolidated PAT at ₹ 62.7 crore in Q4FY25.

Drugmakers Glenmark Pharma, Cipla plan to step up US manufacturing

The US already contributes a significant share, around a quarter, of Cipla's total revenues

Panacea Biotec shares locked in 5% upper circuit; here's what to know

The stock rose as much as 5 per cent during the day to hit an upper circuit of ₹538.55 per share

Is your heartburn pill safe? Panel recommends banning ranitidine in India

An expert panel has recommended suspending ranitidine after tests found cancer-linked NDMA levels in half the samples, bringing India closer to a nationwide ban

AstraZeneca India surrenders marketing approval of prostate cancer drug

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..

US court clears Sun Pharma to launch Leqselvi for alopecia areata treatment

Sun Pharma is now preparing to launch the drug in US markets after facing legal issues since November 2024

Booster shot as India's pharma market grew 8.4% in FY25: Pharmarack

Augmentin remains top-selling medicine brand at Rs 816 crore sales

Strides Pharma initiates Class-II recall of Testosterone Gel in US

The recall was voluntarily initiated by Strides Pharma on March 5, 2025, and remains ongoing. Consignees have been informed about this recall formerly, although public press release has not been issue

Trump says tariffs on chips and pharma imports to be announced soon

President Trump has said tariffs on pharmaceutical and semiconductor imports will be announced shortly, as the US imposes a 27% duty on all imports from India

India's pharma industry gets relief from Trump's reciprocal tariff

US President says India imposes 52% tariff on American imports and engages in currency manipulation and non-tariff barriers

Trump's pharma tariffs threaten global supply chains, patient access

Protectionist policies will raise the prices of active ingredients for these producers, many of whom may have little recourse to return manufacturing to the US in the short term

Will US tariffs succeed in lifting the veil on India's drug safety problem?

Over 30 per cent of Indian pharma exports go to the US, and it provides an even larger proportion of earnings

Zydus Life extends timeline for Sterling Biotech API business acquisition

The company had first disclosed the deal on September 17, 2024, after signing a business transfer agreement (BTA) with SBL

Piramal Pharma arm, Irish firm get UKMHRA approval for Neoatricon in UK

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a medication used in the treatment of low blood pressure and low heart rate in children. Piramal Critical Care (PCC) has secured the commercialisation rights for Neoatricon, the first paediatric strength solution for infusion of Dopamine Hydrochloride, for the EU, the UK, and Norway markets, Piramal Pharma said in a regulatory filing. PCC would be responsible for distributing Neoatricon in these regions, it added. Developed by BrePco Biopharma, Neoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of Dopamine Hydrochloride. It is available in a concentration of 1.5mg/mL in a 30 mL vial and a higher strength containing 4.5mg/mL in a 50 mL vial. Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or ..

Marksans Pharma up 3% as arm secures marketing authorisation for Baclofen

The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received Marketing Authorisation for the product Baclofen 10 mg Tablets from UK MHRA

Generics surge as patent expiry restores mkt pulse, boosting drug volumes

An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in the market after Novartis' patent expired in December 2019

Drugmakers Mallinckrodt, Endo agree to merge in nearly $7 billion deal

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion